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HGF (hepatocyte growth factor) is a pleiotropic cytokine
homologous to the serine protease zymogen plasminogen that
requires canonical proteolytic cleavage to gain functional activity.
The activating proteases are key components of its regulation,
but controversy surrounds their identity. Using quantitative
analysis we found no evidence for activation by uPA (urokinase
plasminogen activator), despite reports that this is a principal
activator of pro-HGF. This was unaffected by a wide range of
experimental conditions, including the use of various molecular
forms of both HGF and uPA, and the presence of uPAR
(uPA receptor) or heparin. In contrast the catalytic domains of
the TTSPs (type-II transmembrane serine proteases) matriptase
and hepsin were highly efficient activators (50% activation
at 0.1 and 3.4 nM respectively), at least four orders of
magnitude more efficient than uPA. PS-SCL (positional-scanning
synthetic combinatorial peptide libraries) were used to identify
consensus sequences for the TTSPs, which in the case of hepsin
corresponded to the pro-HGF activation sequence, demonstrating
a high specificity for this reaction. Both TTSPs were also found to
be efficient activators at the cell surface. Activation of pro-HGF
by PC3 prostate carcinoma cells was abolished by both protease
inhibition and matriptase-targeting siRNA (small interfering
RNA), and scattering of MDCK (Madin–Darby canine kidney)
cells in the presence of pro-HGF was abolished by inhibition of
matriptase. Hepsin-transfected HEK (human embryonic kidney)-
293 cells also activated pro-HGF. These observations demonstrate
that, in contrast with the uPA/uPAR system, the TTSPs matriptase
and hepsin are direct pericellular activators of pro-HGF, and that
together these proteins may form a pathway contributing to their
involvement in pathological situations, including cancer.
Key words: hepatocyte growth factor (HGF), pericellular
proteolysis, plasminogen activation, proteolytic processing,
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INTRODUCTION
HGF (hepatocyte growth factor), also known as scatter factor, is
a polypeptide growth factor produced by mesenchymal cells that
exerts pleiotropic effects in multiple tissues (reviewed in [1]). It
is an important paracrine mediator of epithelial–mesenchymal
cell interactions, affecting many cellular processes, including
proliferation, differentiation, motility, invasion and branching
morphogenesis. As well as being essential for development
[2,3], HGF is also implicated in a variety of physiological and
pathological processes including wound healing, cancer and
cardiovascular disease. These effects are all mediated by the
binding of HGF to a single receptor, the proto-oncogene receptor
tyrosine kinase c-Met [1].
HGF is closely related to the serine protease zymogen
plasminogen, comprising an N-terminal PAN/apple domain,
four kringle domains (compared with five in plasminogen) and
a C-terminal serine protease domain. However, the latter is
enzymatically inactive due in part to mutations in two of the
three residues (His57 and Ser195; the numbering used for the serine
protease domain follows the convention of numbering according
to the sequence of chymotrypsinogen) comprising the serine
protease catalytic triad. The primary binding determinants for
the interaction of HGF with c-Met are contained within the N-
terminal and kringle domains of HGF [4]. Although mediating
high-affinity binding, these interactions are not sufficient for the
activation of c-Met.
A key characteristic that HGF retains from its serine protease
ancestry is the absolute requirement for limited proteolysis to
acquire biological activity. In a similar manner to plasminogen and
other serine protease zymogens, HGF is secreted as a single-chain
precursor form and this pro-HGF form is devoid of signalling
activity. Pro-HGF is activated to a disulphide-bridged, two-chain
molecule by proteolytic cleavage at the canonical Arg15–Val16
bond in the serine protease domain. In the serine proteases, this
cleavage results in conformational rearrangements in the so-called
‘activation domain’ and maturation of the active site. Structural
studies have demonstrated that HGF undergoes corresponding
conformational changes on proteolytic cleavage and that the
rearranged activation domain constitutes an additional binding
site for c-Met [5,6]. The binding of HGF to c-Met is also
thought to involve a large-scale interdomain reorganization [6],
also analogous to that observed in plasminogen [7]. Together these
conformational changes, caused by a single proteolytic cleavage,
enable HGF/c-Met signalling.
Proteolytic activation of pro-HGF clearly plays an essential role
in the function of the HGF/c-Met signalling pathway; however,
the proteases responsible for this key regulatory step and how
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the proteolysis is regulated are not well understood. The only
protease unequivocally demonstrated to be an authentic activator
of pro-HGF is the serine protease HGFA (HGF activator). This
is an efficient activator of HGF in vitro [8] and has been shown
to contribute to the activation of pro-HGF in vivo [9]. HGFA
is activated by thrombin and, consistent with this, it has a role
primarily at sites of tissue injury [10]. HGFA-null mice develop
normally, in contrast with c-Met or HGF-null mice, but have a
partial impairment of tissue repair [9].
Other serine proteases, several of which are pericellular
proteases, have also been demonstrated to activate pro-HGF
in vitro. They include both integral membrane proteins and
proteases associated with membrane receptors or binding sites;
these have key roles in regulating cell behaviour [11] and may
act to regulate the activity of HGF on the surface of target
cells, i.e. those expressing c-Met. Of particular interest in this
respect is the plasminogen activator uPA (urokinase plasminogen
activator), which has been proposed to be an important activator
of HGF [12–15]. These studies were initially prompted by the
homology of HGF and plasminogen, and would provide an
attractive mechanism for the pericellular activation of HGF, as the
activity of uPA is promoted by association with its specific GPI-
anchored receptor uPAR (uPA receptor) on the surface of many
cell types [16]. However, other studies have found no evidence
for activation of pro-HGF by uPA in purified systems [8,17].
The activity of plasmin itself has also been implicated in the
activation of pro-HGF [18,19]. Soluble forms of two TTSPs (type-
II transmembrane serine proteases), matriptase [20] and hepsin
[21,22], have been shown to activate pro-HGF in purified systems,
but their contribution in the pericellular environment is unclear.
In the present paper we assess the contribution of putative
proteolytic activators of pro-HGF by quantitative comparison
of their activities in solution, their P4–P1 substrate specificities
and their activities in the pericellular environment. We find no
evidence for activation of pro-HGF by uPA under a wide variety
of conditions, making it unlikely that it has a biologically relevant
role. In contrast, the TTSPs matriptase and hepsin were found to
be efficient activators, both in solution and, more importantly,
when expressed as transmembrane proteases. Together, these
observations demonstrate that both matriptase and hepsin are
effective proteolytic activators of pro-HGF at the cell surface, and
furthermore that hepsin has specificity characteristics suggesting
that it may be a highly selective activator of pro-HGF.
EXPERIMENTAL
Proteins and reagents
Human urinary uPA was from Merck Serono, pro-uPA was
from Abbott, tPA (tissue plasminogen activator) was from
Boerhinger Ingelheim, and fXIIa (Factor XIIa) and plasmin
were from Enzyme Research Laboratories. Human HGFA was
obtained from R&D Systems and was activated using immobilized
thrombin (Calbiochem). Recombinant human matriptase protease
domain was expressed in Escherichia coli and yeast as descri-
bed previously [23]. Soluble uPAR expressed in Drosophila S2
cells was a gift from Dr Michael Ploug (Finsen Laboratory,
Copenhagen University Hospital, Copenhagen, Denmark). Pro-
HGF expressed in Saccharomyces cerevisiae was a gift from Dr
George Van Woude (Van Andel Research Institute, Grand Rapids,
MI, U.S.A.). The matriptase inhibitor CJ-730 {compound (8) in
[24]} was a gift from Dr Kerstin Uhland (Curacyte AG, Munich,
Germany). The anti-matriptase monoclonal antibody M32 was a
gift from Dr Chen-Yong Lin (Lombardi Cancer Center, George-
town University Medical Center, Washington, DC, U.S.A.).
Expression and purification of pro-HGF
HGF cDNA was PCR-amplified from a random-hexamer-
primed cDNA library, constructed from human fetal lung
MRC-5 cells. PCR products were ligated into pGEM-T Easy
(Promega), transformed into E. coli DH5α and subcloned into
the expression vector pMT-V5HisB. The resulting plasmid pMT-
HGF-V5His was co-transfected with pCoHygro into Drosophila
Schneider S2 cells using CellFectin in serum-free Drosophila
Expression Medium (all reagents from Invitrogen). After
overnight incubation, cells were cultured for 2 days in complete
medium at 27 ◦C in atmospheric air then selected in 300–
500 μg/ml hygromycin B for 5 weeks. Cells stably expressing
HGF were adapted to serum-free medium and expression was
induced with 0.5 mM CuSO4. Conditioned medium was collected
after 7 days. Recombinant pro-HGF was purified from cleared
S2-conditioned medium using metal chelate- and heparin-affinity
chromatography. Conditioned medium was incubated overnight
with Ni-NTA (Ni2+-nitrilotriacetate) agarose (Qiagen) at 4 ◦C,
loaded on to a column and washed with 50 mM sodium phosphate
buffer, pH 8.0, containing 0.3 M NaCl and 20 mM imidazole.
HGF was eluted in the same buffer containing 0.25 M imidazole.
The eluted protein was incubated with heparin–agarose (Sigma–
Aldrich) in 10 mM Tris/HCl, pH 8.0, overnight at 4 ◦C and
was loaded on to a column and washed with 10 mM Tris/HCl,
pH 8.0, containing 0.3 M NaCl. Bound HGF was eluted in 10 mM
Tris/HCl, pH 8.0, containing 1.5 M NaCl.
Expression and purification of soluble hepsin
Human hepsin was subcloned without the transmembrane
domain, spanning residues 47–417. The honeybee melittin
secretion signal sequence was appended to the N-terminus
by PCR, and a His6 tag was appended to the C-terminus.
All PCR products were inserted into pFastBac1 vector
(Invitrogen) via EcoRI and NotI sites and were then sequenced.
The resulting plasmids were used to produce recombinant
baculovirus following the manufacturer’s protocol (Invitrogen).
Sf9 cells were infected at a MOI (multiplicity of infection)
of 5–10 and the activity of hepsin in the supernatant
monitored by hydrolysis of the fluorogenic peptide Ac-KRLR-
ACC (N-acetyl-Lys-Arg-Leu-Arg-7-amino-4-carbamoylmethyl-
coumarin). When maximal activity was achieved, the supernatant
was collected, adjusted to pH 5.0 with 4.0 M sodium acetate
and cleared by centrifugation (15000 g for 10 min). Filtered
medium was loaded on to a Poros® HS column on an AktaTM
FPLC system (GE Healthcare) at 17 ml/min and was washed
with 75 mM sodium acetate, pH 5.0, until the baseline recovered.
Bound proteins were eluted with 50 mM Tris/HCl, pH 8.0,
containing 1.0 M NaCl and dialysed against 50 mM Tris/HCl,
pH 8.0, containing 20 mM NaCl overnight. The dialysed sample
was loaded on to a benzamidine column at 1.5 ml/min, washed
with 50 mM Tris/HCl, pH 8.0, containing 0.2 M NaCl and
eluted with 0.2 M glycine, pH 3.0. Eluted fractions were
immediately neutralized with 2.0 M Tris/HCl, pH 8.0. The
eluate was concentrated and further purified by Sephadex 200
chromatography (GE Healthcare) in 20 mM Tris/HCl, pH 8.0,
containing 0.15 M NaCl. Active hepsin fractions were pooled and
concentrated.
Active-site titration
The molar concentration of active sites for each protease was
determined by active-site titration using 4-methylumbelliferyl
p-guanidinobenzoate (Sigma–Aldrich). Proteases were dissolved
in 50 mM Hepes, pH 7.4, containing 0.1 M NaCl and 0.01%
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Tween 80 and fluorescence was recorded at 25 ◦C in a PerkinElmer
LS50B luminescence spectrometer.
Proteolytic activation of pro-HGF
Recombinant single-chain pro-HGF (10 nM) was incubated with
varying concentrations of the stated protease in 10 mM sodium
phosphate buffer, pH 8.0, containing 0.12 M NaCl, 5 mM EDTA
and 0.01% Tween 80 for 1 h at 37 ◦C. In some experiments
the reactions were also performed in 50 mM Tris/HCl, pH 8.8,
containing 38 mM NaCl and 0.01% Tween 80. Reactions were
terminated by boiling in SDS/PAGE sample buffer containing
0.1 M dithiothreitol. The samples were subjected to SDS/PAGE
(10% gels), transferred on to PVDF membranes (Bio-Rad
Laboratories) and the activation status of HGF determined
by Western blotting using an anti-V5 monoclonal antibody
(Invitrogen) and HRP (horseradish peroxidase)-conjugated rabbit
anti-(mouse IgG) (Dako). The blots were incubated with
ECL (enhanced chemiluminescence) Plus (GE Healthcare)
and visualized either by exposure to Hyperfilm ECL (GE
Healthcare) or by measuring chemiluminescence using a Storm
PhosphorImager® (GE Healthcare) and ImageQuant® software
(Molecular Dynamics).
Quantitative real-time PCR
The expression of matriptase, hepsin, uPA and uPAR was
determined in prostate-derived cell lines using reverse-transcribed
total RNA and specific primer/probe sets in the 7500 Fast Real-
Time PCR System (Applied Biosystems), as described previously
[25].
Cellular activation of pro-HGF
MDCK (Madin–Darby canine kidney), PC3 or hepsin-transfected
HEK (human embryonic kidney)-293 cells were plated in 96-well
plates at 20000 cells/well and cultured overnight. Cells were
washed with PBS before incubation with pro-HGF in a total
of 100 μl of medium for up to 8 h. Conditioned medium was
removed, subjected to SDS/PAGE (10% gels) and analysed for
activation of pro-HGF by Western blotting.
K i determinations and combinatorial peptide library analysis
Inhibition constants for the inhibitors CJ-730 and amiloride
were determined using the substrate Ac-PRLR-AMC (N-acetyl-
Pro-Arg-Leu-Arg-7-amino-4-methylcoumarin) for matriptase,
hepsin and HGFA, and EGR-AMC (H-Glu-Gly-Arg-7-amino-4-
methylcoumarin) for uPA. Substrate hydrolysis was monitored
at 25 ◦C in a SpectraMax Gemini microplate spectrofluorometer
(Molecular Devices). K i values were determined from plots
of Km/Vmax against [I]. PS-SCL (positional-scanning synthetic
combinatorial peptide libraries) were synthesized as described
previously [26] and profiled with recombinant hepsin and
matriptase (expressed in Saccharomyces cerevisiae).
siRNA (small interfering RNA) knockdown of matriptase expression
PC3 cells were transfected with either of two matriptase-specific
siRNAs or universal control siRNAs as described previously
[23]. Knockdown of matriptase expression was confirmed by
Western blotting using the antibody M32, and was greater than
90% compared with both control siRNA and mock-transfected
cells. Cells were analysed for pro-HGF activation 48 h after
transfection.
Figure 1 Expression and purification of pro-HGF
HGF was expressed in Drosophila S2 cells either in the presence (+) or absence (−) of serum and
purified as described in the Experimental section. Samples (50 ng) reduced with dithiothreitol
were analysed by SDS/PAGE followed by either silver staining or Western blotting (probed for
the C-terminal V5-epitope). For the Western blot, only the C-terminal light-chain of HGF (HGF
lc) is detected subsequent to proteolytic activation. HGF hc, HGF heavy-chain.
Generation of cell lines stably expressing hepsin
Full-length hepsin cDNA [IMAGE (Integrated Molecular
Analysis of Genomes and their Expression) clone 5228525]
was ligated into pcDNA3.1(+)-HA to generate the plasmid
pcDNA3.1/HPN-HA and was transfected into HEK-293 cells
using Fugene 6 (Roche); cells were selected for stable expression
in 200 μg/ml ZeocinTM (Invitrogen). Clones were tested for
hepsin expression by Western blotting using an anti-HA
(haemagglutinin) antibody and by TaqMan® quantitative real-
time PCR using an ABI Prism® 7700 instrument (Applied
Biosystems). Two clones stably expressing low and high levels of
hepsin were selected (clones F10 and C6 respectively).
MDCK cell scatter assay
MDCK cells were seeded at a density of 103 cells per well and left
to adhere overnight. Cells were washed with serum-free medium
and treated with 10 ng/ml of either active or pro-HGF, in the
presence or absence of 50 μM CJ-730. After 30 h cells were
washed with PBS and fixed with ice-cold methanol. Images were
taken using a Zeiss inverted microscope fitted with a CCD (charge-
coupled-device) camera using 10× objective. Three independent
experiments were performed with all treatments in duplicate.
RESULTS
Expression of recombinant single-chain pro-HGF
The study of the proteolytic activation of HGF is greatly facilitated
by the availability of homogenous preparations of the single-chain
form of the protein, a problem which has hampered some previous
studies. We expressed HGF in Drosophila S2 cells and, under
serum-free conditions, the recombinant protein was exclusively
in the 92 kDa unactivated, single-chain form, as shown by
SDS/PAGE with reduced samples (Figure 1). In contrast, in
serum-containing medium, there was significant activation of
HGF, as shown by the appearance of both the 55 kDa N-terminal
heavy-chain and the 34 kDa C-terminal light-chain. In some of
the experiments described below, a small amount of activated
HGF can be detected due to the high sample loading, which
was necessary to ensure the detection of low levels of pro-HGF
activation.
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Figure 2 Proteolytic activation of HGF by uPA
Pro-HGF was incubated with varying concentrations of uPA for 1 h at 37◦C. (A and B) HGF expressed in S2 cells was analysed by SDS/PAGE and detected by Western blotting for the C-terminal
V5-epitope. (A) Lane 1, 0 nM uPA control; lanes 2–8, 1, 5, 10, 15, 30, 50 and 100 nM uPA. (B) Lanes 1, 6 and 11, 0 nM uPA controls; lanes 2–5, 8.3, 17, 83 and 167 nM uPA; lanes 7–10, 0.83,
1.7, 3.1 and 6.2 μM uPA. (C) HGF expressed in S. cerevisiae was analysed by SDS/PAGE with silver-stained gels. Lanes 1 and 10, 0 nM uPA controls; lanes 2–8; 0.14, 0.71, 1.4, 2.1, 4.3, 7.1 and
14 nM uPA; lane 9, HGF fully activated by 10 nM HGFA. (D) shows the effect of 0.8 μM uPA and 100 μg/ml heparin and (E) the effect of 2.5 μM uPA and 2.5 μM suPAR (soluble uPAR) on the
proteolytic activation of S2 cell-expressed pro-HGF as indicated. HGF hc, HGF heavy-chain; HGF lc, HGF light-chain.
uPA is not an efficient activator of pro-HGF
To investigate the role of uPA in the activation of HGF, a
fixed concentration of pro-HGF was incubated with varying
concentrations of uPA for 1 h at 37 ◦C and samples were analysed
by SDS/PAGE followed by Western blotting. The latter was
necessary as pro-HGF was used at a relatively low concentration
(10 nM) in these experiments, so as to be below the likely
Km for the reaction, thereby increasing the fractional amount
of substrate hydrolysed. However, no activation of HGF was
observed with concentrations of uPA up to 50 nM (Figure 2A),
with no reduction in the intensity of the 92 kDa pro-HGF band
nor an increase in the 34 kDa HGF light-chain band. Increasing
incubation times for up to 5 h also failed to demonstrate any
activation of pro-HGF (results not shown). Subsequently, the
concentration of uPA was increased up to 3 μM (Figure 2B). Even
under these conditions no activation of pro-HGF was apparent,
with no increase in the intensity of the 34 kDa light-chain band.
However, a reduction in the intensity of both this and the pro-
HGF band was observed, which was probably due to non-specific
proteolytic cleavage of the C-terminal epitope tag at this extremely
high concentration of uPA. Consistent with this interpretation,
non-reduced samples also showed a decrease in intensity of the
single band representing both molecular forms of HGF (results
not shown).
To exclude the possibility that the lack of observed pro-HGF
activation was an artefact, possibly caused by expression of
HGF in Drosophila S2 cells or the presence of the C-terminal
epitope tag, similar experiments were performed with wild-type
HGF expressed in S. cerevisiae. Once again, no activation by
uPA was detectable, although the pro-HGF was readily activated
by a low concentration of HGFA (Figure 2C). In addition, the
experiment shown in Figure 2(A) was repeated under identical
conditions but with the inclusion of plasminogen. Activation of
plasminogen was readily detected at uPA concentrations as low
as 0.2 nM (results not shown), demonstrating that uPA could
activate plasminogen, but not pro-HGF, in the same reaction
mixture.
The uPA used for these experiments was purified from urine and
is known to have a heterogeneous heavy- or A-chain terminating
in Pro155, Arg156 or Phe157, rather than the expected Lys158, due to
the action of carboxypeptidases [27]. It is possible that the lack
of the C-terminal Lys158 renders these forms of uPA unable to
activate pro-HGF, as this residue is thought to be involved in the
plasminogen activator activity of uPA under certain conditions
[28]. Similarly, single-chain pro-uPA itself has been reported to
have significant plasminogen activator activity [29]. However,
neither pro-uPA nor uPA with an intact A-chain, prepared by
plasmin activation of pro-uPA, were able to activate pro-HGF in
experiments similar to those described above (results not shown).
tPA, up to a concentration of 5 μM, was also unable to activate
pro-HGF (results not shown).
HGF can bind to both heparan sulphate and heparin, which
leads to effects on its biological activity by increasing binding
to c-Met [30]. uPA has also been reported to bind heparin via
its kringle domain [31]. As interactions between heparin-binding
proteases and their substrates or inhibitors can be promoted by co-
incident binding to heparin, the effect of heparin on the activation
of pro-HGF by uPA was investigated. As shown in Figure 2(D),
the presence of heparin did not lead to any detectable activation
of HGF.
To determine whether the binding of uPA to its receptor protein
uPAR influenced the activation of pro-HGF, these experiments
were repeated in the presence of equimolar amounts of soluble
uPAR. Once again, no activation of pro-HGF was apparent
(Figure 2E).
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Figure 3 Proteolytic activation of HGF by matriptase and hepsin in solution
Pro-HGF expressed in S2 cells was incubated with varying concentrations of either the matriptase
catalytic domain or the hepsin extracellular domain for 1-h at 37◦C. Activation was detected
by SDS/PAGE followed by Western blotting for the C-terminal V5-epitope. (A) Matriptase (mat)
and (B) hepsin (hep). Lanes 1, 6 and 12, 0 nM protease; lanes 2–5 and 7–11; 0.1, 0.25, 0.5, 1,
2, 4, 8, 16 and 32 nM protease. HGF lc, HGF light-chain.
Alternative molecular forms of HGF
When we isolated the cDNA for HGF, half of the clones sequenced
were found to represent a previously described alternatively
spliced variant lacking five residues (S130FLPS134) in the first
kringle domain. As the relative abundance of the clones suggested
that this variant may represent a substantial proportion of HGF in
vivo, this form was also expressed in S2 cells and its activation
studied. Again, activation of 130–134 pro-HGF by uPA was not
detected, but it was activated by HGFA with similar efficiency to
the full-length protein (results not shown).
Soluble forms of matriptase and hepsin efficiently activate pro-HGF
On the basis of the biochemical data in the present paper, it appears
unlikely that uPA could play any significant role in the biological
activation of pro-HGF. However, members of the TTSP family
may be good candidates, due to their membrane localization.
In sharp contrast with uPA, the isolated catalytic domain of
matriptase was found to be a very efficient activator of pro-HGF,
with activation apparent at sub-nanomolar concentrations of the
protease (Figure 3A). This proteolysis was also specific as no
other proteolytic fragments were observed on silver-stained gels
(results not shown). Similar experiments were performed with a
soluble form of hepsin consisting of the complete extracellular
domain (residues 47–417). Soluble hepsin was also observed to
be an efficient and specific activator of pro-HGF (Figure 3B).
Quantitative comparison of pro-HGF activation
To quantitatively compare the efficiency of pro-HGF activation
by the various proteases, the molar concentration of the
protease active sites was first determined by active-site titration.
Varying concentrations of the proteases were incubated with
a fixed concentration of pro-HGF and the samples were then
Table 1 Relative efficiencies of various proteolytic activators of HGF
The concentration of each protease giving 50 % activation of pro-HGF in 1 h was calculated
by fitting the data from titration curves obtained using at least nine different concentrations
of each protease over a 1000-fold dilution range (results shown in Supplementary Figure S1)
and represent means +− S.D. Incubation with plasmin led to extensive degradation of HGF at
higher concentrations and it was not possible to accurately quantify activation. No activation
was detected with either uPA or tPA at the highest concentrations used (approx. 6 μM), and
results are calculated using a conservative detection limit of 20 % activation. Pro-HGF activating
activity is expressed relative to HGFA, which is set at 100 %.
Protease Concentration givng 50 % activation (nM) Relative activity (%)
HGFA 0.250 +− 0.059 100
Matriptase 0.121 +− 0.027 207
Hepsin 3.39 +− 1.08 7.4
fXIIa 14.0 +− 6.95 1.8
Plasmin >50 nM <0.5
uPA >30 μM <0.001
tPA >30 μM <0.001
subjected to SDS/PAGE and Western blotting for the C-
terminal V5 epitope (see Supplementary Figure S1 available at
http://www.BiochemJ.org/bj/426/bj4260219add.htm). Activation
was quantified as the ratio of the intensities of the activated
light-chain band to the sum of the light-chain and non-cleaved
single-chain bands, and expressed as the concentration of protease
necessary to achieve 50% activation of pro-HGF in 1 h (Table 1).
These results show matriptase to be the most efficient activator
under these conditions, with approx. twice the activity of HGFA.
A known relatively weak activator, fXIIa [8], was found to be
approximately 100-fold less active than matriptase. However,
activation of pro-HGF by either of the plasminogen activators
under these conditions was estimated to be at least four to
five orders of magnitude below that observed with hepsin and
matriptase respectively.
Peptide substrate specificities of matriptase and hepsin
As matriptase and hepsin appear to share a similar protein
substrate specificity as relatively efficient activators of pro-HGF,
the P4–P1 peptide substrate specificities of these two proteases
were compared using fluorogenic PS-SCL with diversity at all
four positions [26]. Both proteases have trypsin-like activity,
with primary specificity for arginine and lysine residues.
The results show that matriptase has no real arginine/lysine
preference at P1 (Supplementary Figure S2A available at
http://www.BiochemJ.org/bj/426/bj4260219add.htm). In con-
trast, hepsin has a very strong preference for an arginine residue
(Supplementary Figure S2B). The optimal P4–P1 substrate
preference for hepsin sequence is Lys-Gln-Leu-Arg (Figure 4),
which exactly matches the activation sequence of pro-HGF. In
contrast, the specificity of matriptase does not match this sequence
well, with the P3–P2 combination of Gln–Leu being particularly
disfavoured, as shown by both the single-fixed position (Figure 4)
and the two-fixed position (Supplementary Figure S2A, upper
two rows) libraries. Therefore although the data from the kinetic
experiments demonstrate that matriptase is the more efficient
activator of pro-HGF, these experiments suggest that hepsin has
a greater specificity for this reaction.
Cellular activation of pro-HGF by matriptase
Matriptase, hepsin and uPA are three of the serine proteases most
often found to be up-regulated in a wide variety of cancers, for
example, in prostate cancer all three are up-regulated together
with uPAR. However, only matriptase and hepsin show a strong
c© The Authors Journal compilation c© 2010 Biochemical Society
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Figure 4 Peptide substrate specificities of matriptase and hepsin in P4–P1 PS-SCL
(A) Matriptase and (B) hepsin substrate preferences were determined in vitro using peptide substrates in fluorogenic assays as described in the Experimental section. In each panel, the initial
velocities of P2, P3, and P4 positions when P1 is fixed (P1 fixed at arginine for hepsin and P1 fixed at lysine for matriptase) are presented. X represents the 19-amino acid equimolar mixture (the
mixture excludes cysteine, and methionine is replaced with the isostere norleucine, n), and O represents the single fixed amino acid. The full data set is presented in Supplementary Figure S2. RFU,
relative fluorescence units.
Table 2 Expression of TTSPs by prostate cell lines
Expression of matriptase and hepsin in prostate cell lines was determined by quantitative
real-time PCR (TaqMan®). Results are shown for PNT1a, an SV40-transformed normal prostate
epithelial cell line, and for three prostate carcinoma cells lines, PC3, LNCaP and DU145.
Relative mRNA levels are shown after normalization for 18S rRNA and are gene-specific. N.D.,
not determined.
Cell line Matriptase Hepsin uPA uPAR
PNT1a <1 <1 N.D. N.D.
PC3 140 <1 160 120
LNCaP 32 380 <1 5
DU145 <1 <1 230 90
correlation with malignancy and they have expression restricted
to malignant epithelial cells, which is the site of c-Met expression
[25]. Therefore we sought to determine whether various prostate
cancer cell lines could activate pro-HGF and whether either
of the TTSPs, hepsin or matriptase, were responsible. Relative
expression of hepsin and matriptase in these cells was determined
by quantitative real-time PCR (Table 2).
PC3 cells, which expressed the highest levels of matriptase but
were devoid of hepsin expression, were found to activate pro-HGF
in a time-dependent manner over a 24 h time period (Figure 5A).
To determine whether this activation was catalysed by matriptase,
we used a matriptase-selective, 3-amidinophenylalanine-based
inhibitor CJ-730 (Figure 5B). CJ-730 inhibits matriptase (K i =
40 nM) [24] and hepsin (K i =185 nM) (K.A. Owen and
V. Ellis, unpublished work) and consistent with this the IC50 for
inhibition of pro-HGF activation by matriptase in solution was
approximately 50 nM (results not shown). However, although CJ-
730 could completely inhibit pro-HGF activation in PC3 cells,
the IC50 value was determined to be approx. 5 μM, 100-fold
above the K i value. This discrepancy suggested that the inhibitory
effect was possibly due to non-specific inhibition of proteases
other than matriptase. Therefore to further substantiate the role
of matriptase in PC3 cells, matriptase expression was knocked
down with matriptase-targeting siRNA, which also effectively
and specifically abolished pro-HGF activation (Figure 5B).
Although activation of pro-HGF can be blocked by inhibition
or down-regulation of matriptase, this could be an indirect effect,
as matriptase has been shown to activate pro-uPA both in solution
[20,32] and on the cell surface [23]. To test whether uPA had
any role in the activation of pro-HGF under these conditions, an
inhibitor of uPA, amiloride (K i=3.6 μM) (K.A. Owen and V. Ellis,
unpublished work), was used. Amiloride at concentrations of up
to 1 mM failed to inhibit the activation of pro-HGF on either PC3
(Figure 5B) or MDCK cells (results not shown), consistent with
the inability of uPA to activate pro-HGF either in solution, in the
presence or absence of uPAR, or on the cell surface.
To confirm that the proteolytic cleavage of pro-HGF by
matriptase led to the generation of biologically active HGF, the
cell-scattering activity of HGF was determined using MDCK
cells. When incubated with either active HGF (Figure 5D) or pro-
HGF (Figure 5E) the cells were observed to scatter, compared with
the tightly packed groups of cells observed in the absence of HGF
(Figure 5C). Pro-HGF-mediated scattering was prevented by the
inclusion of CJ-730, consistent with the inhibition of matriptase-
catalysed pro-HGF activation (Figure 5F).
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Figure 5 Activation of pro-HGF on the surface of cells expressing transmembrane matriptase
(A) Time course of activation of pro-HGF by PC3 cells. Pro-HGF was incubated in serum-free medium in the presence (+) and absence (−) of PC3 cells. Conditioned medium was removed at the
indicated time points and analysed for HGF activation by Western blotting for the C-terminal V5 epitope. (B) PC3 cells were incubated with pro-HGF for 8 h in the presence (+) and absence (−)
of 50 μM matriptase inhibitor CJ-730 or 1 mM uPA inhibitor amiloride. HGF activation was analysed as above. HGF activation data are also shown for cells pre-treated with matriptase-specific
(mat-siRNA) (+) or control (−) siRNA, together with Western blots for matriptase to demonstrate the efficiency of knockdown. In these cellular activation experiments, slight variations in the level of
pro-HGF activation were observed in the different control conditions, but in all cases time- and cell-dependent activation of HGF was clearly observed. (C–F) HGF-mediated MCDK cell scattering.
MDCK cells growing as tight colonies were incubated in the presence or absence of HGF and cell scattering was determined after 30 h. (C) Control MCDK cells in the absence of added HGF.
(D) MDCK cells incubated with active HGF. (E) MDCK cells incubated with pro-HGF. (F) MDCK cells incubated with pro-HGF in the presence of CJ-730. No effect of CJ-730 was observed when
included in incubations with active HGF. HGF lc, HGF light-chain.
Cellular activation of pro-HGF by hepsin
Among the panel of prostate cell lines, LNCaP expresses
significant levels of hepsin but, despite the relative efficiency
and high specificity of hepsin observed in solution, these cells
did not activate pro-HGF above the level of the control PNT1a
cell line (results not shown). Therefore to determine whether
transmembrane hepsin could also activate pro-HGF in the context
of the cell surface, hepsin-negative HEK-293 cells were stably
transfected with full-length hepsin. Two clones were selected
with differing levels of hepsin expression. Figure 6 shows robust
activation of pro-HGF in the highest expressing clone C6 over a
period of 5 h and significant activation was also observed with
the lower expressing F10 clone, by comparison with the parental
HEK-293 cell line. Therefore in these cells, membrane-anchored
hepsin can efficiently activate pro-HGF at the cell surface.
DISCUSSION
The biological activity of HGF is strictly dependent on proteolytic
processing at a canonical site equivalent to the Arg15–Ile16 bond
of chymotrypsinogen, which it retains from its catalytically
active serine protease homologues. It seems likely that multiple
proteases are able to catalyse this cleavage in vivo, at least
in terms of development and normal physiology. None of the
existing knockouts of serine proteases in mice, which includes
all of the proteases studied here, phenocopy the embryonic lethal
Figure 6 Activation of pro-HGF on the surface of cells expressing
transmembrane hepsin
Parental HEK-293 cells and hepsin-transfected HEK-293 cell clones F10 and C6 were incubated
with pro-HGF for the indicated times and HGF activation analysed by Western blotting for the
C-terminal V5 epitope. Relative hepsin expression in the three cell lines as determined by
quantitative real-time PCR was <0.01 for HEK-293 cells, 0.25 for the F10 clone and 1.0 for the
C6 clone. HGF lc, HGF light-chain.
phenotype observed in HGF-knockout mice [2,3]. The aim of this
study was to determine which of the serine proteases reported
previously to be capable of activating pro-HGF are most likely to
have a biologically relevant role, based on their enzyme kinetic
properties, substrate specificities and their ability to activate pro-
HGF in the pericellular environment.
In this study we find no evidence that the plasminogen
activator uPA is a significant activator of pro-HGF, using an
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Table 3 Substrate cleavage specificities of TTSPs and plasminogen activators
The zymogen activation cleavage sequences of pro-HGF are shown together with the cleavage sequences of the authentic uPA protein substrates plasminogen and uPAR, and the activation cleavage
sequences of hepsin and matriptase zymogens. For comparison, the peptide substrate preferences of hepsin and matriptase determined using PS-SCL are shown, together with the substrate preference
of uPA determined previously using a phage-display library [34].
Substrate P4 P3 P2 P1
Pro-HGF Lys Glu Leu Arg
Plasminogen (human) Cys Pro Gly Arg
Plasminogen (bovine) Cys Ser Gly Arg
uPAR Asp Ser Gly Arg
Matriptase zymogen Arg Glu Ala Arg
Hepsin zymogen Pro Val Asp Arg
Hepsin PS-SCL concensus Lys Glu Leu Arg
Matriptase PS-SCL consensus Lys/Arg Lys/Arg Ser/Ala/Pro Lys/Arg
uPA phage consensus Ser Gly Arg
exhaustive range of experimental conditions. These include
various molecular forms of uPA, various molecular forms and
splice variants of pro-HGF, and the presence of uPAR and heparin.
This is surprising in light of the previous reports of activation
by uPA, but perhaps unsurprising when the known substrate
specificity of uPA is considered. uPA is a highly specific serine
protease. Its only authenticated protein substrate, in addition to
plasminogen, is its own receptor uPAR [33], which is cleaved at
a sequence closely resembling the zymogen activation sequence
of plasminogen (Table 3). In contrast, the activation sequence
in pro-HGF resembles neither the sequence of plasminogen nor
peptide sequences identified as optimal for uPA using a substrate
phage-display approach [34] (Table 3). Furthermore, analysis
of results from the latter study reveals that none of the 91
substrate phage clones selected had the HGF residues at P2 or P3
(leucine and glutamine respectively). uPA-specific substrates are
dominated by those with a glycine reside at P2 (Table 3), and large
hydrophobic residues are excluded at this position, consistent with
the unusually restricted S2 pocket in uPA. Therefore there is no
prior reason to suppose that pro-HGF would be a substrate for
uPA.
The reason for the discrepancy between these conclusions is
not immediately apparent, but three observations may have a
bearing on it. First, it has been reported that the activation by
uPA involves a ‘stoichiometric’ interaction between uPA and pro-
HGF [13], rather than the catalytic reaction that would be ex-
pected. Secondly, the effect of uPA has been reported to be
strongly affected by ionic strength [15]. Thirdly, the same study
also found that the catalytic domain of uPA alone was unable to
activate pro-HGF. None of these observations are characteristic
of a typical protease–substrate interaction. The observation of
pro-HGF activation at very low ionic strength [15] suggests
that it is driven by electrostatic interactions, possibly of a non-
specific nature. Consistent with this, the N-terminal kringle and
connecting peptide region of uPA are highly basic with a pI
of 9.4, whereas the region of HGF spanning kringles 3 and 4
is acidic with a pI of 4.8. Therefore non-specific electrostatic
interactions between the N-terminal regions of the two
proteins, promoted at low ionic strength, may underlie the
observed activation by uPA. Nevertheless, we do not observe
activation under similar conditions and we have been unable
to demonstrate such an interaction between uPA and pro-HGF
using a co-immunoprecipitation approach (K.A. Owen, D. Qiu
and V. Ellis, unpublished work). An additional consideration
is that the majority of previous studies have used 125I-labelled
HGF. Our approach of detecting activation by Western blotting
for a C-terminal V5 epitope obviates the need for such chemical
modification, and the introduction of artefacts by the presence
of the C-terminal tag is unlikely as we obtained identical results
using wild-type HGF.
In sharp contrast with the lack of activity of uPA, both the TTSPs
matriptase and hepsin proved to be efficient activators of pro-HGF.
Our quantitative results demonstrate that matriptase is the most
efficient of the known activators, with hepsin having a lower,
but nevertheless substantial, activity. As with previous qualitative
studies [20–22], our quantitative studies utilized truncated soluble
forms of the proteases. However, we further demonstrated that
the full-length transmembrane forms of both matriptase and
hepsin efficiently activated pro-HGF at the cell surface. This
would appear to give both matriptase and hepsin a significant
advantage over HGFA, a soluble protease, as activated HGF can
be specifically generated at its site of action. In most tissues, HGF
is expressed by cells of mesenchymal origin, whereas c-Met,
matriptase and hepsin are expressed by epithelial cells. Therefore
although HGF is a paracrine factor, its activation could be
considered to be autocrine. However, it remains to be determined
whether membrane localization of these proteases confers them
with any kinetic advantage and whether their N-terminal domains
are involved in substrate recognition or presentation, for example
by exosite interactions.
Although HGF activation by matriptase on PC3 cells was
readily detected, no activation was observed on LNCaP cells
which express significant amounts of hepsin. This may be due in
part to the lower efficiency of hepsin as an activator of pro-HGF
in comparison with matriptase, but may also reflect varying levels
of the active forms of these proteases on the cell surface, an issue
that is discussed subsequently. However, the observation of robust
activation on hepsin-transfected HEK-293 cells demonstrates
that, under suitable conditions, both of these TTSPs can have
potentially significant roles as activators of pro-HGF.
The P4–P1 substrate specificity of matriptase and hepsin,
determined using PS-SCL, in which one position is varied at a
time, revealed that hepsin has a very clear preference for arginine
at P1, whereas matriptase does not discriminate between arginine
and lysine at this position, in accordance with results published
previously [21,32]. This is consistent with the presence of an
arginine residue at P1 of the pro-HGF activation sequence (Lys-
Gln-Leu-Arg). Interestingly the PS-SCL consensus for hepsin
exactly matches the pro-HGF activation sequence (Table 3),
whereas the consensus for matriptase does not, and is particularly
disfavoured at the P3–P2 sequence of Gln–Leu. Serine protease
substrate specificity often does not conform well to linear peptide
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sequences, due in part to conformational constrains in the
substrate. Therefore the close agreement in the case of hepsin
suggests that the core P4–P1 sequence of pro-HGF may be
sufficient for recognition by hepsin, whereas additional features
of the pro-HGF sequence and/or fold may be needed to contribute
to its activation by matriptase.
A significant corollary of the observed pericellular activation
of pro-HGF is that these TTSPs must possess a significant
degree of proteolytic activity under the conditions used, and
therefore that they have become activated from their single-
chain zymogen forms. Unusually for serine protease zymogens,
some TTSPs appear to have the capacity for autoactivation
when expressed as soluble truncated forms. This has been
observed for both matriptase and hepsin, and also TMPRSS2
(transmembrane protease, serine 2), TMPRSS3, matriptase-
2/TMPRSS6 and matriptase-3/TMPRSS7 [34a]. We have also
observed autoactivation of full-length transmembrane hepsin (D.
Qiu and V. Ellis, unpublished observations).
Activation of serine protease zymogens is a highly regulated
process, and autoactivation is usually prevented by the sequence
N-terminal of the proteolytic activation site being incompatible
with the substrate specificity of the active protease. Analysis
of the activation sequences of matriptase and hepsin (Table 3),
reveals that the matriptase sequence is a reasonable match
to its own substrate specificity, although the hepsin sequence
contains a disfavoured aspartate residue at P2. Therefore
although autoactivation of these protease zymogens can be
demonstrated, its efficiency and functional relevance has yet to
be demonstrated.
Despite the lack of direct activation by uPA, compelling
evidence that the plasminogen activation system has a role in
the biological activity of HGF comes from in vivo observations
in mice deficient in components of this proteolytic system.
For example, liver regeneration is impaired in both uPA- and
plasminogen-null mice, concomitantly with a reduction in pro-
HGF activation [19,35]. However, these observations do not
demonstrate a direct role for uPA, or plasmin. HGF is known to
associate with components of the extracellular matrix, including
heparan sulphate proteoglycan, thrombospondin, fibronectin and
vitronectin [36,37]. The activity of the plasminogen activation
system can lead to the degradation of these components, either
directly or by plasmin activation of matrix metalloproteases, and
plasminogen-dependent release of HGF from the extracellular
matrix has been demonstrated [18]. The activation of pro-
HGF is also increased in mice null for TIMP (tissue
inhibitor of metalloproteinases)-1 [38], consistent with an
increase in matrix metalloprotease-mediated extracellular matrix
degradation. Therefore it appears likely that the role of the
plasminogen activation system in the activation of HGF is in
releasing sequestered pro-HGF from the extracellular matrix,
making it available for pericellular activation by transmembrane
serine proteases.
The activation of pro-HGF in vivo is clearly redundant and
mediated by a variety of proteases. However, this does not rule
out the involvement of individual proteases in specific situations,
especially pathological situations, and may be of particular
relevance in cancer. Although c-Met is a proto-oncogene, and
activating mutations are found in many cancers, its activation
by HGF is thought to play an important role in oncogenesis
and tumour development [1] and there is evidence that increased
HGF/c-Met signalling promotes the progression of prostate cancer
[39]. We have shown in an analysis of 40 protease-related genes in
prostate cancer that the expression of both matriptase and hepsin is
highly correlated with both malignancy and disease progression,
and that hepsin was the protease gene most highly correlated with
disease stage [25]. Therefore it is possible that the activation of
pro-HGF by either matriptase or hepsin provides a mechanism
for the involvement of these TTSPs in the development of
cancer.
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Figure S1 Quantification of pro-HGF activation by serine proteases in
solution
Western blots such as those shown in Figures 2 and 3 in the main paper were quantified for
both pro-HGF and HGF light-chain by ECL using a PhosphorImager®. Results are represented
as the ratio of HGF light-chain to the total HGF detected on the blot and are expressed as a
percentage. Results are means +− S.D. for a minimum of three data sets. The results were fitted
to a four-parameter logistic function by non-linear regression. Results are shown for (A) HGFA,
(B) the matriptase catalytic domain, (C) the hepsin extracellular domain and (D) fXIIa.
1 To whom correspondence should be addressed (email v.ellis@uea.ac.uk).
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Figure S2 Peptide substrate specificities of matriptase and hepsin in a P4–P1 positional scanning synthetic combinatorial library
(A) Matriptase and (B) hepsin substrate preferences were determined in vitro using peptide substrates in fluorogenic assays as described in the Experimental section in the main paper. The upper
two rows of each panel show the initial velocities associated with each substrate in two-position fixed sublibraries, normalized with the highest initial velocity observed, and are presented in a
two-dimensional format scaled by grey intensity. The number in the square at the bottom of each sublibrary represents the highest activity in the sublibrary as a proportion of the highest overall
activity. The two positions in the substrate that are varied contain an equimolar mixture of 19 amino acids (the mixture excludes cysteine, and methionine is replaced with the isostere norleucine, n)
for a total of 361 substrates per well. The lower two rows of each panel show the initial velocities of P2, P3 and P4 positions when P1 is fixed (P1 is fixed as an arginine residue for hepsin and P1
is fixed at lysine and arginine for matriptase). X represents the 19-amino acid equimolar mixture (the mixture excludes cysteine, and methionine is replaced with the isostere norleucine, n), and O
represents the single fixed amino acid.
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